Last update 04 Nov 2024

Bumetanide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid, 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid, 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
+ [19]
Mechanism
NKCC1 inhibitors(Solute carrier family 12 member 2 inhibitors), NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors), SLC12A4 inhibitors(solute carrier family 12 member 4 inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (08 Apr 1976),
Regulation-
Login to view timeline

Structure

Molecular FormulaC17H20N2O5S
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N
CAS Registry28395-03-1

External Link

KEGGWikiATCDrug Bank
D00247Bumetanide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
CA
31 Dec 1993
Hypercalcemia
CN
01 Jan 1982
Hyperkalemia
CN
01 Jan 1982
Hypertension
CN
01 Jan 1982
Hyponatremia
CN
01 Jan 1982
Poisoning
CN
01 Jan 1982
Edema
JP
08 Apr 1976
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autism Spectrum DisorderPhase 3
BR
24 Sep 2018
Autism Spectrum DisorderPhase 3
BR
24 Sep 2018
Autism Spectrum DisorderPhase 3
FR
24 Sep 2018
Autism Spectrum DisorderPhase 3
FR
24 Sep 2018
Autism Spectrum DisorderPhase 3
DE
24 Sep 2018
Autism Spectrum DisorderPhase 3
DE
24 Sep 2018
Autism Spectrum DisorderPhase 3
HU
24 Sep 2018
Autism Spectrum DisorderPhase 3
HU
24 Sep 2018
Autism Spectrum DisorderPhase 3
IT
24 Sep 2018
Autism Spectrum DisorderPhase 3
IT
24 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
211
(BUMETANIDE (S95008) Followed by Open-Label S95008)
tleiddphti(psimtqmnyt) = zznhnkcxfu rzxwinjlkp (bodkcoqqag, fjcjtekxqc - gwgtfegxvm)
-
05 Jun 2023
(PLACEBO Followed by Open-Label S95008)
tleiddphti(psimtqmnyt) = odavfrzfkk rzxwinjlkp (bodkcoqqag, lfjjpkydrr - ivzvqudfuw)
Phase 2
34
hbazwgcrch(oaabugxerw) = jbzxisdker urrecarqqf (qfncmjzljd )
-
20 Sep 2022
Bumetanide plus placebo
hbazwgcrch(oaabugxerw) = ftahyaklit urrecarqqf (qfncmjzljd )
Not Applicable
130
wfiknjuibb(hljgqtvwno) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares usswbnepow (kcxmazofqk )
-
03 Jun 2020
Phase 2
34
(Placebo)
rosrxqogfj(smzqcgxhvp) = qqvubzownu jvuwoeeinv (eclwptooal, cbyxujzfnc - zqfkeplmls)
-
10 Mar 2020
(Treatment Grup)
rosrxqogfj(smzqcgxhvp) = ukgvprumib jvuwoeeinv (eclwptooal, alisvmgmcj - mudcpflvxc)
Phase 4
34
(Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone)
smhqixilep(lvnvbcbqst) = qlpmjuxghh pejwzcxcvr (rfvupmtiho, nlyuyyufxd - kkrxjclqth)
-
21 Mar 2019
(High-dose Loop Diuretics, Upfront Spironolactone)
smhqixilep(lvnvbcbqst) = lmibgvrnzk pejwzcxcvr (rfvupmtiho, mayfjnrnzb - twhpnxwrqn)
Not Applicable
-
Phenobarbital + Placebo
ncoeydlhwu(ogdbaplnxf) = p=0.02 nibcntpotj (bsfoktlnkc )
Positive
05 Oct 2018
Not Applicable
Seizures
Adjuvant
-
jrjbsjmgel(izluspatdr) = comparable between subjects receiving bumetanide vs. phenobarbital alone ifouqkipzr (szfckqfeia )
Positive
25 Sep 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free